Where Will Gartner Stock Be in 5 Years?
If you’ve ever wondered what it’s like to invest in…
Buy
54
CDNA Quote, Financials, Valuation and Earnings
Last price:
$16.96
Seasonality move
:
27.49%
Day range:
$16.57 - $17.14
52-week range:
$12.90 - $34.84
Dividend yield:
0%
P/E ratio:
14.74x
P/S ratio:
2.81x
P/B ratio:
2.49x
Volume:
982.3K
Avg. volume:
1.2M
1-year change:
7.08%
Market cap:
$943.8M
Revenue:
$333.8M
EPS (TTM):
$1.15
Analysts' Opinion
-
Consensus RatingCareDx has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.29, CareDx has an estimated upside of 72.78% from its current price of $16.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $16.95.
Fair Value
-
According to the consensus of 7 analysts, CareDx has 72.78% upside to fair value with a price target of $29.29 per share.
CDNA vs. S&P 500
-
Over the past 5 trading days, CareDx has underperformed the S&P 500 by -0.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CareDx does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CareDx has grown year-over-year revenues for 4 quarters straight. In the most recent quarter CareDx reported revenues of $84.7M.
Earnings Growth
-
CareDx has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CareDx reported earnings per share of -$0.19.
Enterprise value:
712.9M
EV / Invested capital:
1.88x
Price / LTM sales:
2.81x
EV / EBIT:
--
EV / Revenue:
2.06x
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
35.38x
Price / Operating cash flow:
48.38x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$234.3M
Return On Assets:
12.38%
Net Income Margin (TTM):
16.99%
Return On Equity:
18.96%
Return On Invested Capital:
18.96%
Operating Margin:
-9.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $319.6M | $275.1M | $346.4M | $72M | $84.7M | |
| Gross Profit | $208.3M | $173.1M | $234.3M | $46.1M | $56.3M | |
| Operating Income | -$82.5M | -$103M | -$42.4M | -$22.6M | -$8M | |
| EBITDA | -$65.3M | -$82.7M | -$23M | -$17.3M | -$3.1M | |
| Diluted EPS | -$1.51 | -$3.47 | $1.15 | -$0.38 | -$0.19 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $438.7M | $411.5M | $371.4M | $303.1M | $350.2M | |
| Total Assets | $541.2M | $546.7M | $528.2M | $452.4M | $489.6M | |
| Current Liabilities | $45.7M | $66.9M | $71.8M | $70.2M | $85.3M | |
| Total Liabilities | $69.7M | $89.2M | $108.2M | $196.2M | $110.3M | |
| Total Equity | $471.5M | $457.5M | $420M | $256.2M | $379.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | -$34.4M | $26.8M | -$15.3M | -$26.6M | |
| Cash From Investing | -$87.2M | $82.9M | -$26.8M | $27.7M | $1.3M | |
| Cash From Financing | -$6.5M | -$29.7M | -$5M | -$1.3M | -$643K | |
| Free Cash Flow | -$21.6M | -$42.3M | $20.1M | -$16.8M | -$28.2M | |
CDNA
Sector
Market Cap
$943.8M
$34.8M
Price % of 52-Week High
48.65%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
7.08%
-41.1%
Beta (5-Year)
2.273
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$17.03
200-day SMA
Sell
Level
$23.14
Bollinger Bands (100)
Sell
Level
17.09 - 22.71
Chaikin Money Flow
Buy
Level
22.3M
20-day SMA
Buy
Level
$16.35
Relative Strength Index (RSI14)
Sell
Level
49.85
ADX Line
Buy
Level
13.11
Williams %R
Neutral
Level
-23.7171
50-day SMA
Sell
Level
$17.55
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
79.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.4221)
Buy
CA Score
(Annual)
Level (0.0733)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-5.2721)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Stock Forecast FAQ
In the current month, CDNA has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CDNA average analyst price target in the past 3 months is $29.29.
-
Where Will CareDx Stock Be In 1 Year?
According to analysts, the consensus estimate is that CareDx share price will rise to $29.29 per share over the next 12 months.
-
What Do Analysts Say About CareDx?
Analysts are divided on their view about CareDx share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CareDx is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is CareDx's Price Target?
The price target for CareDx over the next 1-year time period is forecast to be $29.29 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CDNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CareDx is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDNA?
You can purchase shares of CareDx via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CareDx shares.
-
What Is The CareDx Share Price Today?
CareDx was last trading at $16.96 per share. This represents the most recent stock quote for CareDx. Yesterday, CareDx closed at $16.95 per share.
-
How To Buy CareDx Stock Online?
In order to purchase CareDx stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus has flown under the radar, but the numbers tell…
Celsius Stock Forecast: Will Earnings Spark Another Surge?
Energy drink seller Celsius Holdings, Inc. (NASDAQ:CELH) has reported somewhat…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
